<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02994940</url>
  </required_header>
  <id_info>
    <org_study_id>948256</org_study_id>
    <nct_id>NCT02994940</nct_id>
  </id_info>
  <brief_title>Modified Pre-operative Oral Doses Acetaminophen Versus Intravenous Acetaminophen</brief_title>
  <acronym>MODIV-APAP</acronym>
  <official_title>Modified Pre-operative Oral Doses Acetaminophen Versus Intravenous Acetaminophen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acetaminophen is frequently used as an adjunct for pain management in pediatric surgical&#xD;
      patients. The drug is available in an over the counter, inexpensive oral form as well as a&#xD;
      considerably more expensive intravenous form. This study will compare opioid requirements and&#xD;
      acetaminophen plasma levels post operatively for two dosing regimens to compare oral versus&#xD;
      intravenous routes given pre operatively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to compare opioid utilization in post-operative patients&#xD;
      undergoing tonsillectomy and adenoidectomy, between IV and PO acetaminophen. Secondarily, it&#xD;
      will provide information regarding possible cost savings, pharmacokinetics and safety between&#xD;
      these two regimens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Actual">July 3, 2019</completion_date>
  <primary_completion_date type="Actual">July 3, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Dose of Opioid</measure>
    <time_frame>Within 24hrs</time_frame>
    <description>Total dose of opioid, in morphine equivalents, that the patient receives for breakthrough pain in the 24 hour period following surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Severe Pain Score of 7 or Higher</measure>
    <time_frame>24 hrs period following surgery</time_frame>
    <description>A secondary endpoint is the proportion of patients with pain scores in the severe pain range (7 or higher) on numeric pain rating scale of 0 to 10; higher score more severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Acetaminophen Level 1 - End of Surgery</measure>
    <time_frame>at the end of surgery, about 1 hour after IV Dose</time_frame>
    <description>mg/L acetaminophen in the plasma at the end of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Acetaminophen Level 2 - 3 Hours After IV Study Drug Administration</measure>
    <time_frame>Outcome will be measured 3hrs post first IV Dose</time_frame>
    <description>mg/L acetaminophen in the plasma 3 hours after IV study drug administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Tonsillectomy</condition>
  <condition>Adenoidectomy</condition>
  <arm_group>
    <arm_group_label>Oral Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>already included in arm/group descriptions</description>
    <arm_group_label>Intravenous Acetaminophen</arm_group_label>
    <arm_group_label>Oral Acetaminophen</arm_group_label>
    <other_name>OFIRMEV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ages 3 years to 17 years scheduled for tonsillectomy and adenoidectomy for&#xD;
             obstructive sleep apnea with or without additional minor procedures such as sleep&#xD;
             endoscopy, unilateral or bilateral myringotomy, insertion of tympanostomy tubes and/or&#xD;
             ear exam. ( Minor additional procedures that are frequently combined with&#xD;
             tonsillectomy and adenoidectomy but are not commonly considered to have pain that is&#xD;
             significantly greater than the tonsillectomy and adenoidectomy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who meet University of California Davis Children's Hospital (UCDCH) criteria&#xD;
             for Pediatric Intensive Care Unit (PICU) admission: on home oxygen pre-operatively,&#xD;
             exhibit airway obstruction when awake (stertor above larynx, stridor at larynx), sleep&#xD;
             study with apnea hypoxia index greater than 25 or sleep oxygen saturation nadir &lt;80%,&#xD;
             cardiac disease, difficult intubation.&#xD;
&#xD;
          -  Patients with a known allergy to acetaminophen&#xD;
&#xD;
          -  Patients with known hepatic insufficiency or severe hepatic disease&#xD;
&#xD;
          -  Patients with known Glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
          -  Patients who are malnourished (ie lower levels of glutathione)&#xD;
&#xD;
          -  Patients with severe renal impairment as defined by calculated creatinine clearance&#xD;
             &lt;20 ml/min (per modified Schwarz equation)&#xD;
&#xD;
          -  Patients who are pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cathy Lammers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Children's Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>December 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2016</study_first_posted>
  <results_first_submitted>November 3, 2020</results_first_submitted>
  <results_first_submitted_qc>December 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 9, 2020</results_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02994940/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02994940/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Acetaminophen</title>
          <description>Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.&#xD;
Acetaminophen</description>
        </group>
        <group group_id="P2">
          <title>Intravenous Acetaminophen</title>
          <description>Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.&#xD;
Acetaminophen</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive study medications: Study drug not available prior to anesthesia induction</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive study medications: vomited after ingestion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive study medications: red dye allergy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Completed subjects (n=66) used for analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Oral Acetaminophen</title>
          <description>Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.&#xD;
Acetaminophen</description>
        </group>
        <group group_id="B2">
          <title>Intravenous Acetaminophen</title>
          <description>Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.&#xD;
Acetaminophen</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="B2" value="6" lower_limit="4.3" upper_limit="7"/>
                    <measurement group_id="B3" value="5" lower_limit="4" upper_limit="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.3" lower_limit="16.6" upper_limit="25.3"/>
                    <measurement group_id="B2" value="20.6" lower_limit="18.3" upper_limit="28.2"/>
                    <measurement group_id="B3" value="20.2" lower_limit="17.5" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentile weight for age</title>
          <units>percentile</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.0" lower_limit="27.0" upper_limit="86.3"/>
                    <measurement group_id="B2" value="45.0" lower_limit="29.3" upper_limit="84.8"/>
                    <measurement group_id="B3" value="49.5" lower_limit="29.8" upper_limit="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Dose of Opioid</title>
        <description>Total dose of opioid, in morphine equivalents, that the patient receives for breakthrough pain in the 24 hour period following surgery.</description>
        <time_frame>Within 24hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Acetaminophen</title>
            <description>Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.&#xD;
Acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Acetaminophen</title>
            <description>Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.&#xD;
Acetaminophen</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dose of Opioid</title>
          <description>Total dose of opioid, in morphine equivalents, that the patient receives for breakthrough pain in the 24 hour period following surgery.</description>
          <units>mcg/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.6" lower_limit="119.6" upper_limit="193.0"/>
                    <measurement group_id="O2" value="125.4" lower_limit="102.8" upper_limit="150.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hodges Lehman estimator</param_type>
            <param_value>21.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>44.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Severe Pain Score of 7 or Higher</title>
        <description>A secondary endpoint is the proportion of patients with pain scores in the severe pain range (7 or higher) on numeric pain rating scale of 0 to 10; higher score more severe.</description>
        <time_frame>24 hrs period following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Acetaminophen</title>
            <description>Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.&#xD;
Acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Acetaminophen</title>
            <description>Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.&#xD;
Acetaminophen</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Severe Pain Score of 7 or Higher</title>
          <description>A secondary endpoint is the proportion of patients with pain scores in the severe pain range (7 or higher) on numeric pain rating scale of 0 to 10; higher score more severe.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.851</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Acetaminophen Level 1 - End of Surgery</title>
        <description>mg/L acetaminophen in the plasma at the end of surgery</description>
        <time_frame>at the end of surgery, about 1 hour after IV Dose</time_frame>
        <population>2 patients in Oral did not have sample obtained for level; 1 patient in IV had value below 10 mg/L limit of quantification</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Acetaminophen</title>
            <description>Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.&#xD;
Acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Acetaminophen</title>
            <description>Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.&#xD;
Acetaminophen</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Acetaminophen Level 1 - End of Surgery</title>
          <description>mg/L acetaminophen in the plasma at the end of surgery</description>
          <population>2 patients in Oral did not have sample obtained for level; 1 patient in IV had value below 10 mg/L limit of quantification</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="16.5" upper_limit="27.8"/>
                    <measurement group_id="O2" value="20" lower_limit="17" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.109</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hodges Lehman estimator</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Acetaminophen Level 2 - 3 Hours After IV Study Drug Administration</title>
        <description>mg/L acetaminophen in the plasma 3 hours after IV study drug administration</description>
        <time_frame>Outcome will be measured 3hrs post first IV Dose</time_frame>
        <population>Acetaminophen plasma levels obtained 3 hours after start of the IV study drug in patients with samples obtained; these were not available for 8 Oral and 9 IV subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Acetaminophen</title>
            <description>Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.&#xD;
Acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Acetaminophen</title>
            <description>Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.&#xD;
Acetaminophen</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Acetaminophen Level 2 - 3 Hours After IV Study Drug Administration</title>
          <description>mg/L acetaminophen in the plasma 3 hours after IV study drug administration</description>
          <population>Acetaminophen plasma levels obtained 3 hours after start of the IV study drug in patients with samples obtained; these were not available for 8 Oral and 9 IV subjects.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="15.0" upper_limit="21.0"/>
                    <measurement group_id="O2" value="11" lower_limit="10.3" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hodges Lehman estimator</param_type>
            <param_value>7.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.0</ci_lower_limit>
            <ci_upper_limit>8.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Acetaminophen</title>
          <description>Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.&#xD;
Acetaminophen</description>
        </group>
        <group group_id="E2">
          <title>Intravenous Acetaminophen</title>
          <description>Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.&#xD;
Acetaminophen</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard L. Applegate II MD</name_or_title>
      <organization>UC Davis Anesthesiology &amp; Pain Medicine</organization>
      <phone>916-734-5028</phone>
      <email>rapplegate@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

